版本:
中国

BRIEF-Summit to extend ongoing trial of Ezutromid in patients with Duchenne disorder

March 27 Summit Therapeutics Plc

* Summit Therapeutics Plc - decision follows interim safety review by phaseout dmd's independent data monitoring committee

* Summit to extend ongoing phaseout dmd clinical trial of Ezutromid in patients with dmd

* Summit Therapeutics Plc - will proceed with planned extension phase of phaseout dmd

* Summit Therapeutics Plc - now applied for regulatory approval to extend phaseout dmd from uk medicines, healthcare products regulatory agency, ethics committee

* Summit Therapeutics Plc - in addition to extension phase of trial, regulatory submissions also include addition of a safety arm

* Summit Therapeutics - safety arm to allow enrolment of patients from phase 1 clinical trials of ezutromid but didn't meet inclusion criteria for phaseout dmd Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐